{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T10:12:41Z","timestamp":1781950361757,"version":"3.54.5"},"reference-count":73,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2018.0751","type":"journal-article","created":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T14:41:57Z","timestamp":1540996917000},"source":"Crossref","is-referenced-by-count":24,"title":["Lyme Neuroborreliosis"],"prefix":"10.3238","author":[{"given":"Sebastian","family":"Rauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kastenbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Fingerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Peter","family":"Hunfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Iko","family":"Huppertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Dersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2018,11,9]]},"reference":[{"key":"10.3238\/arztebl.2018.0751_ref1","doi-asserted-by":"crossref","unstructured":"Dersch R, Toews I, Sommer H, et al.: Methodological quality of guidelines for management of Lyme neuroborreliosis. BMC Neurol 2015; 15: 242","DOI":"10.1186\/s12883-015-0501-3"},{"key":"10.3238\/arztebl.2018.0751_ref2","doi-asserted-by":"crossref","unstructured":"Dersch R, Freitag MH, Schmidt S, et al.: Efficacy and safety of pharmacological treatments for neuroborreliosis\u2014protocol for a systematic review. Syst Rev 2014; 3: 117","DOI":"10.1186\/2046-4053-3-117"},{"key":"10.3238\/arztebl.2018.0751_ref3","doi-asserted-by":"crossref","unstructured":"Dersch R, Freitag MH, Schmidt S, et al.: Efficacy and safety of pharmacological treatments for acute Lyme neuroborreliosis\u2014a systematic review. Eur J Neurol 2015; 22: 1249\u201359","DOI":"10.1111\/ene.12744"},{"key":"10.3238\/arztebl.2018.0751_ref4","unstructured":"Rauer S, Kastenbauer S, et al.: S3 Leitlinie Neuroborreliose. Deutsche Gesellschaft f\u00fcr Neurologie (ed.) 2018. Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. www.dgn.org\/leitlinien."},{"key":"10.3238\/arztebl.2018.0751_ref5","doi-asserted-by":"crossref","unstructured":"Oschmann P, Dorndorf W, Hornig C, et al.: Stages and syndromes of neuroborreliosis. J Neurol 1998; 245: 262\u201372","DOI":"10.1007\/s004150050216"},{"key":"10.3238\/arztebl.2018.0751_ref6","doi-asserted-by":"crossref","unstructured":"Hansen K, Lebech AM: The clinical and epidemiological profile of Lyme neuroborreliosis in Denmark 1985\u20131990. A prospective study of 187 patients with borrelia burgdorferi specific intrathecal antibody production. Brain 1992; 115: 399\u2013423","DOI":"10.1093\/brain\/115.2.399"},{"key":"10.3238\/arztebl.2018.0751_ref7","doi-asserted-by":"crossref","unstructured":"Kaiser R: Variable CSF findings in early and late Lyme neuroborreliosis: a follow-up study in 47 patients. J Neurol 1994; 242: 26\u201336","DOI":"10.1007\/BF00920571"},{"key":"10.3238\/arztebl.2018.0751_ref8","doi-asserted-by":"crossref","unstructured":"Djukic M, Schmidt-Samoa C, Lange P, et al.: Cerebrospinal fluid findings in adults with acute Lyme neuroborreliosis. J Neurol 2012; 259: 630\u20136","DOI":"10.1007\/s00415-011-6221-8"},{"key":"10.3238\/arztebl.2018.0751_ref9","doi-asserted-by":"crossref","unstructured":"Kristoferitsch W, Sluga E, Graf M, et al.: Neuropathy associated with acrodermatitis chronica atrophicans. Clinical and morphological features. Ann N Y Acad Sci 1988; 539: 35\u201345","DOI":"10.1111\/j.1749-6632.1988.tb31836.x"},{"key":"10.3238\/arztebl.2018.0751_ref10","doi-asserted-by":"crossref","unstructured":"Kindstrand E, Nilsson BY, Hovmark A, et al.: Peripheral neuropathy in acrodermatitis chronica atrophicans\u2014a late borrelia manifestation. Acta Neurol Scand 1997; 95: 338\u201345","DOI":"10.1111\/j.1600-0404.1997.tb00222.x"},{"key":"10.3238\/arztebl.2018.0751_ref11","doi-asserted-by":"crossref","unstructured":"Mygland A, Skarpaas T, Ljostad U: Chronic polyneuropathy and Lyme disease. Eur J Neurol 2006; 13: 1213\u20135","DOI":"10.1111\/j.1468-1331.2006.01395.x"},{"key":"10.3238\/arztebl.2018.0751_ref12","doi-asserted-by":"crossref","unstructured":"Hess A, Buchmann J, Zettl UK, et al.: Borrelia burgdorferi central nervous system infection presenting as an organic schizophrenialike disorder. Biol Psychiatry 1999; 45: 795","DOI":"10.1016\/S0006-3223(98)00277-7"},{"key":"10.3238\/arztebl.2018.0751_ref13","doi-asserted-by":"crossref","unstructured":"Christen HJ: Lyme neuroborreliosis in children. Ann Med 1996; 28: 235\u201340","DOI":"10.3109\/07853899609033125"},{"key":"10.3238\/arztebl.2018.0751_ref14","doi-asserted-by":"crossref","unstructured":"Huppertz HI, Sticht-Groh V: Meningitis due to borrelia burgdorferi in the initial stage of Lyme disease. Eur J Pediatr 1989; 148: 428\u201330","DOI":"10.1007\/BF00595904"},{"key":"10.3238\/arztebl.2018.0751_ref15","doi-asserted-by":"crossref","unstructured":"Huppertz HI, Bartmann P, Heininger U, et al.: Rational diagnostic strategies for Lyme borreliosis in children and adolescents: recommendations by the Committee for Infectious Diseases and Vaccinations of the German Academy for Pediatrics and Adolescent Health. Eur J Pediatr 2012; 171: 1619\u201324","DOI":"10.1007\/s00431-012-1779-4"},{"key":"10.3238\/arztebl.2018.0751_ref16","doi-asserted-by":"crossref","unstructured":"Halperin JJ, Logigian EL, Finkel MF, Pearl RA: Practice parameters for the diagnosis of patients with nervous system Lyme borreliosis (Lyme disease). Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1996; 46: 619\u201327","DOI":"10.1212\/WNL.46.3.619"},{"key":"10.3238\/arztebl.2018.0751_ref17","unstructured":"Fingerle V, Eiffert H, Gessner A, et al.: Lyme borreliose. In: Podbielski A, Abele-Horn M, Hermann M, Kniehl E, Mauch H, R\u00fcssmann H (eds.): MiQ \u2013 Qualit\u00e4tsstandars in der mikrobiologisch-infektiologischen Untersuchung. 2nd edition. M\u00fcnchen, Jena: Elsevier, Urban & Fischer 2017."},{"key":"10.3238\/arztebl.2018.0751_ref18","doi-asserted-by":"crossref","unstructured":"Stanek G, Fingerle V, Hunfeld KP, et al.: Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect 2011; 17: 69\u201379","DOI":"10.1111\/j.1469-0691.2010.03175.x"},{"key":"10.3238\/arztebl.2018.0751_ref19","doi-asserted-by":"crossref","unstructured":"Wilske B, Fingerle V, Schulte-Spechtel U: Microbiological and serological diagnosis of Lyme borreliosis. FEMS Immunol Med Microbiol 2007; 49: 13\u201321","DOI":"10.1111\/j.1574-695X.2006.00139.x"},{"key":"10.3238\/arztebl.2018.0751_ref20","doi-asserted-by":"crossref","unstructured":"Ljostad U, Skarpaas T, Mygland A: Clinical usefulness of intrathecal antibody testing in acute Lyme neuroborreliosis. Eur J Neurol 2007; 14: 873\u20136","DOI":"10.1111\/j.1468-1331.2007.01799.x"},{"key":"10.3238\/arztebl.2018.0751_ref21","doi-asserted-by":"crossref","unstructured":"Reiber H, Peter JB: Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J Neurol Sci 2001; 184: 101\u201322","DOI":"10.1016\/S0022-510X(00)00501-3"},{"key":"10.3238\/arztebl.2018.0751_ref22","doi-asserted-by":"crossref","unstructured":"Kaiser R: Neuroborreliosis. J Neurol 1998; 245: 247\u201355","DOI":"10.1007\/s004150050214"},{"key":"10.3238\/arztebl.2018.0751_ref23","doi-asserted-by":"crossref","unstructured":"Dessau RB, Fingerle V, Gray J, et al.: The lymphocyte transformation test for the diagnosis of Lyme borreliosis has currently not been shown to be clinically useful. Clin Microbiol Infect 2014; 20: O786-7","DOI":"10.1111\/1469-0691.12583"},{"key":"10.3238\/arztebl.2018.0751_ref24","doi-asserted-by":"crossref","unstructured":"Lantos PM, Auwaerter PG, Wormser GP: A systematic review of borrelia burgdorferi morphologic variants does not support a role in chronic Lyme disease. Clin Infect Dis 2014; 58: 663\u201371","DOI":"10.1093\/cid\/cit810"},{"key":"10.3238\/arztebl.2018.0751_ref25","doi-asserted-by":"crossref","unstructured":"Jowett N, Gaudin RA, Banks CA, Hadlock TA: Steroid use in Lyme disease-associated facial palsy is associated with worse long-term outcomes. Laryngoscope 2017; 127: 1451\u20138","DOI":"10.1002\/lary.26273"},{"key":"10.3238\/arztebl.2018.0751_ref26","doi-asserted-by":"crossref","unstructured":"Oksi J, Nikoskelainen J, Hiekkanen H, et al.: Duration of antibiotic treatment in disseminated Lyme borreliosis: a double-blind, randomized, placebo-controlled, multicenter clinical study. Eur J Clin Microbiol Infect Dis 2007; 26: 571\u201381","DOI":"10.1007\/s10096-007-0340-2"},{"key":"10.3238\/arztebl.2018.0751_ref27","doi-asserted-by":"crossref","unstructured":"Pfister HW, Preac-Mursic V, Wilske B, et al.: Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. J Infect Dis 1991; 163: 311\u20138","DOI":"10.1093\/infdis\/163.2.311"},{"key":"10.3238\/arztebl.2018.0751_ref28","doi-asserted-by":"crossref","unstructured":"Ogrinc K, Lusa L, Lotric-Furlan S, et al.: Course and outcome of early European Lyme neuroborreliosis (Bannwarth syndrome): clinical and laboratory findings. Clin Infect Dis 2016; 63: 346\u201353","DOI":"10.1093\/cid\/ciw299"},{"key":"10.3238\/arztebl.2018.0751_ref29","doi-asserted-by":"crossref","unstructured":"Kaiser R: [Clinical courses of acute and chronic neuroborreliosis following treatment with ceftriaxone]. Nervenarzt 2004; 75: 553\u20137","DOI":"10.1007\/s00115-003-1560-z"},{"key":"10.3238\/arztebl.2018.0751_ref30","doi-asserted-by":"crossref","unstructured":"Berglund J, Stjernberg L, Ornstein K, et al.: 5-y follow-up study of patients with neuroborreliosis. Scand J Infect Dis 2002; 34: 421\u20135","DOI":"10.1080\/00365540110080421"},{"key":"10.3238\/arztebl.2018.0751_ref31","doi-asserted-by":"crossref","unstructured":"Dersch R, Hottenrott T, Schmidt S, et al.: Efficacy and safety of pharmacological treatments for Lyme neuroborreliosis in children: a systematic review. BMC Neurol 2016; 16: 189","DOI":"10.1186\/s12883-016-0708-y"},{"key":"10.3238\/arztebl.2018.0751_ref32","doi-asserted-by":"crossref","unstructured":"Koedel U, Fingerle V, Pfister HW: Lyme neuroborreliosis-epidemiology, diagnosis and management. Nat Rev Neurol 2015; 11: 446\u201356","DOI":"10.1038\/nrneurol.2015.121"},{"key":"10.3238\/arztebl.2018.0751_ref33","doi-asserted-by":"crossref","unstructured":"Halperin JJ: Nervous system Lyme disease. Infect Dis Clin North Am 2015; 29: 241\u201353","DOI":"10.1016\/j.idc.2015.02.002"},{"key":"10.3238\/arztebl.2018.0751_ref34","doi-asserted-by":"crossref","unstructured":"Feder HM, Jr., Johnson BJ, O\u2018Connell S, et al.: A critical appraisal of \u201echronic Lyme disease\u201c. N Engl J Med 2007; 357: 1422\u201330","DOI":"10.1056\/NEJMra072023"},{"key":"10.3238\/arztebl.2018.0751_ref35","doi-asserted-by":"crossref","unstructured":"Dersch R, Sommer H, Rauer S, Meerpohl JJ: Prevalence and spectrum of residual symptoms in Lyme neuroborreliosis after pharmacological treatment: a systematic review. J Neurol 2016; 263: 17\u201324","DOI":"10.1007\/s00415-015-7923-0"},{"key":"10.3238\/arztebl.2018.0751_ref36","doi-asserted-by":"crossref","unstructured":"Klempner MS, Hu LT, Evans J, et al.: Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001; 345: 85\u201392","DOI":"10.1056\/NEJM200107123450202"},{"key":"10.3238\/arztebl.2018.0751_ref37","doi-asserted-by":"crossref","unstructured":"Fallon BA, Keilp JG, Corbera KM, et al.: A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 2008; 70: 992\u20131003","DOI":"10.1212\/01.WNL.0000284604.61160.2d"},{"key":"10.3238\/arztebl.2018.0751_ref38","doi-asserted-by":"crossref","unstructured":"Krupp LB, Hyman LG, Grimson R, et al.: Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 2003; 60: 1923\u201330","DOI":"10.1212\/01.WNL.0000071227.23769.9E"},{"key":"10.3238\/arztebl.2018.0751_ref39","doi-asserted-by":"crossref","unstructured":"Kaplan RF, Trevino RP, Johnson GM, et al.: Cognitive function in post-treatment Lyme disease: do additional antibiotics help? Neurology 2003; 60: 1916\u201322","DOI":"10.1212\/01.WNL.0000068030.26992.25"},{"key":"10.3238\/arztebl.2018.0751_ref40","doi-asserted-by":"crossref","unstructured":"Patel R, Grogg KL, Edwards WD, et al.: Death from inappropriate therapy for lyme disease. Clin Infect Dis 2000; 31: 1107\u20139","DOI":"10.1086\/318138"},{"key":"10.3238\/arztebl.2018.0751_ref41","doi-asserted-by":"crossref","unstructured":"Holzbauer SM, Kemperman MM, Lynfield R: Death due to community-associated clostridium difficile in a woman receiving prolonged antibiotic therapy for suspected lyme disease. Clin Infect Dis 2010; 51: 369\u201370","DOI":"10.1086\/654808"},{"key":"10.3238\/arztebl.2018.0751_ref42","doi-asserted-by":"crossref","unstructured":"Marzec NS, Nelson C, Waldron PR, et al.: Serious bacterial infections acquired during treatment of patients given a diagnosis of chronic lyme disease\u2014United States. MMWR Morb Mortal Wkly Rep 2017; 66: 607\u20139","DOI":"10.15585\/mmwr.mm6623a3"},{"key":"10.3238\/arztebl.2018.0751_ref43","doi-asserted-by":"crossref","unstructured":"Wilking H, Stark K: Trends in surveillance data of human lyme borreliosis from six federal states in eastern Germany, 2009\u20132012. Ticks Tick Borne Dis 2014; 5: 219\u201324","DOI":"10.1016\/j.ttbdis.2013.10.010"},{"key":"10.3238\/arztebl.2018.0751_ref44","doi-asserted-by":"crossref","unstructured":"Muller I, Freitag MH, Poggensee G, et al.: Evaluating frequency, diagnostic quality, and cost of lyme borreliosis testing in Germany: a retrospective model analysis. Clin Dev Immunol 2012; 2012: 595427","DOI":"10.1155\/2012\/595427"},{"key":"10.3238\/arztebl.2018.0751_ref45","doi-asserted-by":"crossref","unstructured":"Kaiser R, Kern A, Kampa D, Neumann-Haefelin D: Prevalence of antibodies to borrelia burgdorferi and tick-borne encephalitis virus in an endemic region in southern Germany. Zentralbl Bakteriol 1997; 286: 534\u201341","DOI":"10.1016\/S0934-8840(97)80057-6"},{"key":"10.3238\/arztebl.2018.0751_ref46","doi-asserted-by":"crossref","unstructured":"Stanek G, Flamm H, Groh V, et al.: Epidemiology of borrelia infections in Austria. Zentralbl Bakteriol Mikrobiol Hyg A 1987; 263: 442\u20139","DOI":"10.1016\/S0176-6724(87)80106-2"},{"key":"10.3238\/arztebl.2018.0751_ref47","doi-asserted-by":"crossref","unstructured":"Wilking H, Fingerle V, Klier C, et al.: Antibodies against borrelia burgdorferi sensu lato among adults, Germany, 2008\u20132011. Emerg Infect Dis 2015; 21: 107\u201310","DOI":"10.3201\/eid2101.140009"},{"key":"10.3238\/arztebl.2018.0751_ref48","unstructured":"Heininger U, Zimmermann T, Schoerner C, et al.: Zeckenstich und Lyme-Borreliose \u2013 Eine epidemiologische Untersuchung im Raum Erlangen. Monatsschrift Kinderheilkunde 1993; 141: 874\u20137."},{"key":"10.3238\/arztebl.2018.0751_ref49","doi-asserted-by":"crossref","unstructured":"Maiwald M, Oehme R, March O, et al.: Transmission risk of borrelia burgdorferi sensu lato from Ixodes ricinus ticks to humans in southwest Germany. Epidemiol Infect 1998; 121: 103\u20138","DOI":"10.1017\/S0950268898008929"},{"key":"10.3238\/arztebl.2018.0751_ref50","doi-asserted-by":"crossref","unstructured":"Paul H, Gerth HJ, Ackermann R: Infectiousness for humans of Ixodes ricinus containing borrelia burgdorferi. Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology 1987; 263: 473\u20136","DOI":"10.1016\/S0176-6724(87)80113-X"},{"key":"10.3238\/arztebl.2018.0751_ref51","doi-asserted-by":"crossref","unstructured":"Henningsson AJ, Malmvall BE, Ernerudh J, et al.: Neuroborreliosis \u2013 an epidemiological, clinical and healthcare cost study from an endemic area in the south-east of Sweden. Clin Microbiol Infect 2010; 16: 1245\u201351","DOI":"10.1111\/j.1469-0691.2009.03059.x"},{"key":"10.3238\/arztebl.2018.0751_ref52","doi-asserted-by":"crossref","unstructured":"Hassler D, Zoller L, Haude M, et al.: [Lyme borreliosis in an endemic region in Europe. Prevalence of antibodies and clinical spectrum]. Dtsch Med Wochenschr 1992; 117: 767\u201374","DOI":"10.1055\/s-2008-1062374"},{"key":"10.3238\/arztebl.2018.0751_ref53","doi-asserted-by":"crossref","unstructured":"Pasareanu AR, Mygland A, Kristensen O: A woman in her 50s with manic psychosis. Tidsskr Nor Laegeforen 2012; 132: 537\u20139","DOI":"10.4045\/tidsskr.11.0683"},{"key":"10.3238\/arztebl.2018.0751_ref54","doi-asserted-by":"crossref","unstructured":"Roelcke U, Barnett W, Wilder-Smith E, et al.: Untreated neuroborreliosis: Bannwarth\u2018s syndrome evolving into acute schizophrenia-like psychosis. A case report. J Neurol 1992; 239: 129\u201331","DOI":"10.1007\/BF00833910"},{"key":"10.3238\/arztebl.2018.0751_ref55","unstructured":"Markeljevic J, Sarac H, Rados M: Tremor, seizures and psychosis as presenting symptoms in a patient with chronic lyme neuroborreliosis (LNB). Coll Antropol 2011; 35, Suppl 1: 313\u20138."},{"key":"10.3238\/arztebl.2018.0751_ref56","unstructured":"Csaszar T, Patakfalvi A: [Differential diagnostic problems in lyme disease (Borrelia infection resulting in acute exogenous psychosis)]. Orv Hetil 1994; 135: 2269\u201371"},{"key":"10.3238\/arztebl.2018.0751_ref57","doi-asserted-by":"crossref","unstructured":"Wittwer B, Pelletier S, Ducrocq X, et al.: Cerebrovascular events in lyme neuroborreliosis. J Stroke Cerebrovasc Dis 2015; 24: 1671\u20138","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.03.056"},{"key":"10.3238\/arztebl.2018.0751_ref58","doi-asserted-by":"crossref","unstructured":"Zajkowska J, Garkowski A, Moniuszko A, et al.: Vasculitis and stroke due to lyme neuroborreliosis\u2014a review. Infect Dis (Lond) 2015; 47: 1\u20136","DOI":"10.3109\/00365548.2014.961544"},{"key":"10.3238\/arztebl.2018.0751_ref59","doi-asserted-by":"crossref","unstructured":"Schmutzhard E, Willeit J, Gerstenbrand F: Meningopolyneuritis Bannwarth with focal nodular myositis. A new aspect in lyme borreliosis. Klin Wochenschr 1986; 64: 1204\u20138","DOI":"10.1007\/BF01728463"},{"key":"10.3238\/arztebl.2018.0751_ref60","doi-asserted-by":"crossref","unstructured":"Reimers CD, de Koning J, Neubert U, et al.: Borrelia burgdorferi myositis: report of eight patients. J Neurol 1993; 240: 278\u201383","DOI":"10.1007\/BF00838161"},{"key":"10.3238\/arztebl.2018.0751_ref61","doi-asserted-by":"crossref","unstructured":"Wilke M, Eiffert H, Christen HJ, Hanefeld F: Primarily chronic and cerebrovascular course of lyme neuroborreliosis: case reports and literature review. Arch Dis Child 2000;83:67\u201371","DOI":"10.1136\/adc.83.1.67"},{"key":"10.3238\/arztebl.2018.0751_ref62","doi-asserted-by":"crossref","unstructured":"Nordberg M, Forsberg P, Nyman D, et al.: Can ELISPOT be applied to a clinical setting as a diagnostic utility for neuroborreliosis? Cells 2012; 1: 153\u201367.","DOI":"10.3390\/cells1020153"},{"key":"10.3238\/arztebl.2018.0751_ref63","doi-asserted-by":"crossref","unstructured":"Marques A, Telford SR, III, Turk SP, et al.: Xenodiagnosis to detect borrelia burgdorferi infection: a first-in-human study. Clin Infect Dis 2014; 58: 937\u201345","DOI":"10.1093\/cid\/cit939"},{"key":"10.3238\/arztebl.2018.0751_ref64","doi-asserted-by":"crossref","unstructured":"Bockenstedt LK, Radolf JD: Xenodiagnosis for posttreatment lyme disease syndrome: resolving the conundrum or adding to it? Clin Infect Dis 2014; 58: 946\u20138","DOI":"10.1093\/cid\/cit942"},{"key":"10.3238\/arztebl.2018.0751_ref65","unstructured":"Hartmann F, Mueller-Marienburg H: Indirekter Neurotoxinnachweis durch den \u201eVisual Contrast Sensitivity\u201c-Test bei Patienten mit einer chronischen Borreliose. Die Medizinische Welt \u2013 aus der Wissenschaft in die Praxis 2003; 54: 248\u201351."},{"key":"10.3238\/arztebl.2018.0751_ref66","doi-asserted-by":"crossref","unstructured":"Stricker RB, Winger EE: Decreased CD57 lymphocyte subset in patients with chronic lyme disease. Immunology Letters 2001; 76: 43\u20138","DOI":"10.1016\/S0165-2478(00)00316-3"},{"key":"10.3238\/arztebl.2018.0751_ref67","doi-asserted-by":"crossref","unstructured":"Smit PW, Kurkela S, Kuusi M, Vapalahti O: Evaluation of two commercially available rapid diagnostic tests for lyme borreliosis. Eur J Clin Microbiol Infect Dis 2015; 34: 109\u201313","DOI":"10.1007\/s10096-014-2217-5"},{"key":"10.3238\/arztebl.2018.0751_ref68","doi-asserted-by":"crossref","unstructured":"Klempner MS, Baker PJ, Shapiro ED, et al.: Treatment trials for post-lyme disease symptoms revisited. Am J Med 2013; 126: 665\u20139","DOI":"10.1016\/j.amjmed.2013.02.014"},{"key":"10.3238\/arztebl.2018.0751_ref69","doi-asserted-by":"crossref","unstructured":"Brouwers MC, Kho ME, Browman GP, et al.: AGREE II: advancing guideline development, reporting, and evaluation in health care. Prev Med 2010; 51: 421\u20134","DOI":"10.1016\/j.ypmed.2010.08.005"},{"key":"10.3238\/arztebl.2018.0751_ref70","doi-asserted-by":"crossref","unstructured":"Mygland A, Ljostad U, Fingerle V, et al.: EFNS guidelines on the diagnosis and management of European lyme neuroborreliosis. Eur J Neurol 2009.","DOI":"10.1111\/j.1468-1331.2009.02862.x"},{"key":"10.3238\/arztebl.2018.0751_ref71","doi-asserted-by":"crossref","unstructured":"Halperin JJ, Shapiro ED, Logigian E, et al.: Practice parameter: treatment of nervous system lyme disease (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2007; 69: 91\u2013102","DOI":"10.1212\/01.wnl.0000265517.66976.28"},{"key":"10.3238\/arztebl.2018.0751_ref72","unstructured":"Rauer S, Kaiser R, K\u00f6lmel HW, et al.: Neuroborreliose. In: Diener HC, Weimar C (eds.): Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. Stuttgart, New York: Georg Thieme Verlag 2012: 513\u201322."},{"key":"10.3238\/arztebl.2018.0751_ref73","doi-asserted-by":"crossref","unstructured":"Balshem H, Helfand M, Schunemann HJ, et al.: GRADE guidelines: 3. rating the quality of evidence. J Clin Epidemiol 2011; 64: 401\u20136","DOI":"10.1016\/j.jclinepi.2010.07.015"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2018.0751","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T14:12:12Z","timestamp":1638799932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2018.0751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,9]]},"references-count":73,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2018.0751","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,9]]}}}